This Seminar presents the current best practice for the diagnosis and management of
bladder cancer. The scope of this Seminar ranges from current challenges in pathology …

Context This overview presents the updated European Association of Urology (EAU)
guidelines for non–muscle-invasive bladder cancer (NMIBC), TaT1, and carcinoma in situ …

Abstract Background The European Association of Urology (EAU) prognostic factor risk
groups for non–muscle-invasive bladder cancer (NMIBC) are used to provide …

Bladder cancer is a highly prevalent disease and is associated with substantial morbidity,
mortality and cost. Environmental or occupational exposures to carcinogens, especially …

Purpose: Although associated with an overall favorable survival rate, the heterogeneity of
non-muscle invasive bladder cancer (NMIBC) affects patients' rates of recurrence and …

Context The incidence of bladder cancer is three to four times greater in men than in women.
However, women are diagnosed with more advanced disease at presentation and have less …

Context To improve the prognosis of upper tract urothelial carcinoma (UTUC), clinicians
have used neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) before or after …

Bladder cancer is a complex disease associated with high morbidity and mortality rates if not
treated optimally. Awareness of haematuria as the major presenting symptom is paramount …

Background Although radical cystectomy (RC) is the standard of care for patients with
bacillus Calmette-Guérin (BCG)-unresponsive high-risk non–muscle-invasive bladder …

Stage T1 bladder cancers invade the lamina propria of the bladder and, despite sharing
many of the genetic features of muscle-invasive bladder cancers, are classified as non …